<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29554">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721966</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457F3302</org_study_id>
    <secondary_id>2016-000814-31</secondary_id>
    <nct_id>NCT02721966</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement</brief_title>
  <acronym>MAXIMISE</acronym>
  <official_title>MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52 Week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non Steroidal Anti-inflammatory Drugs (NSAIDs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or
      300 mg in the management of axial manifestations in PsA patients who have failed to respond
      to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according
      to assessment of spondyloarthritis international society (ASAS) recommendations for the
      treatment of axial spondyloarthritis (AxSpA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2016</start_date>
  <completion_date type="Anticipated">May 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of spondyloarthritis international society (ASAS) 20 response</measure>
    <time_frame>at week 12</time_frame>
    <description>Proportion of patients with response to treatment (300 mg AIN457) as assessed by the ASAS 20 criteria at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of spondyloarthritis international society (ASAS) 20 response</measure>
    <time_frame>at week 12</time_frame>
    <description>Proportion of patiens with response to treatment (150 mg AIN457) as assessed by the ASAS 20 criteria at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of spondyloarthritis international society (ASAS) 40 response</measure>
    <time_frame>at week 12</time_frame>
    <description>Proportion of patiens with response to treatment as assessed by the Assessment of spondyloarthritis international society (ASAS) 40 criteria at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath ankylosing spondylitis disease activity index (BASDAI) 50 response</measure>
    <time_frame>at week 12</time_frame>
    <description>BASDAI 50 response is defined as at least 50% improvement (decrease) in total BASDAI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spinal pain visual analog scale (VAS) scale</measure>
    <time_frame>at baseline, at week 12</time_frame>
    <description>Change from baseline in spinal pain VAS scale at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index</measure>
    <time_frame>at baseline, at week 12</time_frame>
    <description>Change from baseline in SPARCC enthesitis index at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Health assessment questionnaire - disability index (HAQ-DI)</measure>
    <time_frame>at baseline, at week 12</time_frame>
    <description>Change from baseline in HAQ-DI at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional assessment of chronic illness therapy fatigue scale (FACIT-Fatigue)</measure>
    <time_frame>at baseline, at week 12</time_frame>
    <description>Change from baseline in FACIT-Fatigue at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of spondyloarthritis international society (ASAS) Health Index</measure>
    <time_frame>at baseline, at week 12</time_frame>
    <description>Change from baseline in ASAS Health Index at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) 20 response</measure>
    <time_frame>at week 12</time_frame>
    <description>Proportion of patients with response to treatment as assessed by the ACR 20 criteria at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Adverese Events</measure>
    <time_frame>at week 12</time_frame>
    <description>physical examinations, vital signs, adverse events, laboratory parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">495</enrollment>
  <condition>Axial Psoratic Arthritis</condition>
  <arm_group>
    <arm_group_label>AIN457 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab dose 1 or 300 mg sc injection every 4 week for remaining 40 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <description>Anti IL-17a monoclonal antibody</description>
    <arm_group_label>AIN457 dose 1</arm_group_label>
    <arm_group_label>AIN457 dose 2</arm_group_label>
    <arm_group_label>AIN457 Placebo</arm_group_label>
    <other_name>Secukinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457 Placebo</intervention_name>
    <description>Placebo matching AIN457</description>
    <arm_group_label>AIN457 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed

          -  Diagnosis of psoriatic arthritis classified by Classification criteria for psoriatic
             arthritis (CASPAR) criteria

          -  Active spinal disease defined by Bath ankylosing spondylitis disease activity index
             (BASDAI) score ≥ 4

          -  Spinal Pain visual analog scale (VAS) ≥ 40 (on a VAS 100 scale)

          -  Inadequate Response to at least 2 non-steroidal anti-inflammatory drugs over a 4
             weeks period

        Exclusion Criteria:

          -  History of exposure to other IL-17 or IL-23 inhibitor biologic drug

          -  History of exposure to previous biologic disease modifying anti-rheumatic drugs
             (DMARDs) (Tumor necrosis factor (TNF) blockers or Ustekinumab)

          -  Current treatment with disease modifying anti-rheumatic drugs (DMARDs) other than
             Methotrexate

          -  Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone,
             morphine)

          -  Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing
             infectious or malignant process, obtained within 3 months prior to screening and
             evaluated by a qualified physician

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>63800</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruntal</city>
        <zip>792 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen-Bory</city>
        <zip>30599</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51013</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <state>Cedex</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>PARIS Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Mande</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heviz</city>
        <zip>8380</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>H-3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugo</city>
        <state>Galicia</state>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>CH 8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leytonstone</city>
        <state>London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wigan</city>
        <zip>WN6 9EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>March 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Assessment of spondyloarthritis international society (ASAS)</keyword>
  <keyword>ASAS</keyword>
  <keyword>axial</keyword>
  <keyword>Psoriatic Arthritis (PsA)</keyword>
  <keyword>PsA</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
